Literature DB >> 34156188

Challenging dilemmas of low grade, non-invasive bladder cancer: a narrative review.

Fernando Korkes1,2, Phillipe E Spiess3,4, Herney Andres Garcia-Perdomo5, Andrea Necchi6.   

Abstract

PURPOSE: To describe the current scientific knowledge and clinical experience in low-grade-non-muscle-invasive bladder cancer (LG-NMIBC) patients in challenging scenarios.
MATERIALS AND METHODS: Medline, Embase, Google Scholar, and Cochrane Central were searched until March 2021.
RESULTS: A total of 841 studies were identified, and abstracts were analyzed. Twenty-one relevant studies were then identified and reviewed. After all, information was gathered from 16 studies, the authors discussed the specific topics, and expert opinions were also included in the discussion. There have been some studies that can help us to have some insights on how to manage these patients. Very distinctive strategies have been reported in the literature, mainly anecdotally or in small randomized studies. Some of these treatments outlined in the present manuscript include repeated TURBTs, chemoablation, BCG immunoablation, partial cystectomy, radical cystectomy, radiotherapy, chemotherapy, and future perspectives. In the current manuscript, we have combined these strategies in a proposed algorithm.
CONCLUSION: For those LG-NMIBC patients in challenging scenarios, we have found repeated TURBTs, chemoablation, BCG immunoablation, partial cystectomy, radical cystectomy, radiotherapy, and chemotherapy are attractive modalities to treat them effectively. Also, the current manuscript proposes an algorithm to overcome these challenges. Copyright® by the International Brazilian Journal of Urology.

Entities:  

Keywords:  Carcinoma, Transitional Cell; Review Literature as Topic; Urinary Bladder Neoplasms

Mesh:

Substances:

Year:  2022        PMID: 34156188      PMCID: PMC9060175          DOI: 10.1590/S1677-5538.IBJU.2021.0259

Source DB:  PubMed          Journal:  Int Braz J Urol        ISSN: 1677-5538            Impact factor:   3.050


  28 in total

1.  Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder.

Authors:  Truls Gårdmark; Malcolm Carringer; Eva Beckman; Per-Uno Malmström
Journal:  Urology       Date:  2005-09       Impact factor: 2.649

2.  Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder.

Authors:  C L Amling; J B Thrasher; H A Frazier; R K Dodge; J E Robertson; D F Paulson
Journal:  J Urol       Date:  1994-01       Impact factor: 7.450

3.  Radiochemotherapy after transurethral resection is an effective treatment method in T1G3 bladder cancer.

Authors:  Z Akçetin; J Todorov; E Tüzel; D G Engehausen; F S Krause; R Sauer; K M Schrott; C Rödel
Journal:  Anticancer Res       Date:  2005 May-Jun       Impact factor: 2.480

Review 4.  BCG treatment of existing Ta, T1 tumours or carcinoma in situ of the bladder.

Authors:  H Akaza
Journal:  Eur Urol       Date:  1995       Impact factor: 20.096

5.  Report From the International Society of Urological Pathology (ISUP) Consultation Conference On Molecular Pathology Of Urogenital Cancers. II. Molecular Pathology of Bladder Cancer: Progress and Challenges.

Authors:  Joshua I Warrick; Margaret A Knowles; Allory Yves; Theo van der Kwast; David J Grignon; Glen Kristiansen; Lars Egevad; Arndt Hartmann; Liang Cheng
Journal:  Am J Surg Pathol       Date:  2020-07       Impact factor: 6.394

Review 6.  European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.

Authors:  Marko Babjuk; Maximilian Burger; Eva M Compérat; Paolo Gontero; A Hugh Mostafid; Joan Palou; Bas W G van Rhijn; Morgan Rouprêt; Shahrokh F Shariat; Richard Sylvester; Richard Zigeuner; Otakar Capoun; Daniel Cohen; José Luis Dominguez Escrig; Virginia Hernández; Benoit Peyronnet; Thomas Seisen; Viktor Soukup
Journal:  Eur Urol       Date:  2019-08-20       Impact factor: 20.096

Review 7.  European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.

Authors:  J Alfred Witjes; Harman Max Bruins; Richard Cathomas; Eva M Compérat; Nigel C Cowan; Georgios Gakis; Virginia Hernández; Estefania Linares Espinós; Anja Lorch; Yann Neuzillet; Mathieu Rouanne; George N Thalmann; Erik Veskimäe; Maria J Ribal; Antoine G van der Heijden
Journal:  Eur Urol       Date:  2020-04-29       Impact factor: 20.096

8.  Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer?

Authors:  Marco Racioppi; Luca Di Gianfrancesco; Mauro Ragonese; Giuseppe Palermo; Emilio Sacco; Pier Francesco Bassi
Journal:  Int Braz J Urol       Date:  2019 Mar-Apr       Impact factor: 1.541

9.  Endoclips as novel fiducial markers in trimodality bladder-preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient outcomes.

Authors:  Muhammad Shahbaz; Asif Ammar; Yuliang Wang; Zeeshan Farhaj; Liang Qiao; Jun Niu
Journal:  Int Braz J Urol       Date:  2021 Jan-Feb       Impact factor: 1.541

View more
  1 in total

1.  Upper tract urothelial carcinoma and bladder cancer in review in this number of International Brazilian Journal of Urology.

Authors:  Luciano A Favorito
Journal:  Int Braz J Urol       Date:  2022 May-Jun       Impact factor: 1.541

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.